Harvard University’s financial struggles have led to severe cuts imposed by the Trump administration, leaving researchers in need of alternative funding models. To address this, a private equity firm, İş Private Equity, has stepped in with a $39 million investment for a biological research lab at Harvard’s T.H. Chan School of Public Health. The lab, run by professor Gökhan Hotamışlıgil, will focus on developing new therapies for metabolic conditions.
The collaboration also includes the launch of Enlila, a biotech company that will invest in any promising drug candidates emerging from Hotamșılıgil’s laboratory. This arrangement is seen as a potential model for funding future academic research at Harvard and other institutions facing similar financial challenges.
Source: https://www.statnews.com/2025/06/16/harvard-lab-to-be-financed-by-39-million-from-private-equity-firm-from-turkey